Pays
Auteurs
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration Tocilizumab

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Japon1003
Toru Hirano16
Japon Sauf Toru Hirano" 987
Toru Hirano Sauf Japon" 0
Japon Et Toru Hirano 16
Japon Ou Toru Hirano 1003
Corpus6869
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 16.
Ident.Authors (with country if any)Title
000432 Kosuke Ebina [Japon] ; Toru Hirano [Japon] ; Yuichi Maeda [Japon] ; Wataru Yamamoto [Japon] ; Motomu Hashimoto [Japon] ; Koichi Murata [Japon] ; Tohru Takeuchi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Akira Onishi [Japon] ; Sadao Jinno [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Keiichi Yamamoto [Japon] ; Atsushi Kumanogoh [Japon] ; Makoto Hirao [Japon]Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
000D54 Kosuke Ebina [Japon] ; Motomu Hashimoto [Japon] ; Wataru Yamamoto [Japon] ; Toru Hirano [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Akira Onishi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Keiichi Yamamoto [Japon] ; Yuichi Maeda [Japon] ; Koichi Murata [Japon] ; Sadao Jinno [Japon] ; Tohru Takeuchi [Japon] ; Makoto Hirao [Japon] ; Atsushi Kumanogoh [Japon] ; Hideki Yoshikawa [Japon]Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-
000D55 Kosuke Ebina [Japon] ; Motomu Hashimoto [Japon] ; Wataru Yamamoto [Japon] ; Toru Hirano [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Akira Onishi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Keiichi Yamamoto [Japon] ; Yuichi Maeda [Japon] ; Koichi Murata [Japon] ; Sadao Jinno [Japon] ; Tohru Takeuchi [Japon] ; Makoto Hirao [Japon] ; Atsushi Kumanogoh [Japon] ; Hideki Yoshikawa [Japon]Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
000E22 Kosuke Ebina [Japon] ; Motomu Hashimoto [Japon] ; Wataru Yamamoto [Japon] ; Toru Hirano [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Akira Onishi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Keiichi Yamamoto [Japon] ; Yuichi Maeda [Japon] ; Koichi Murata [Japon] ; Sadao Jinno [Japon] ; Tohru Takeuchi [Japon] ; Makoto Hirao [Japon] ; Atsushi Kumanogoh [Japon] ; Hideki Yoshikawa [Japon]Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study
001376 Michihito Katayama [Japon] ; Kaori Ota [Japon] ; Noriko Nagi-Miura [Japon] ; Naohito Ohno [Japon] ; Norikazu Yabuta [Japon] ; Hiroshi Nojima [Japon] ; Atsushi Kumanogoh [Japon] ; Toru Hirano [Japon]Ficolin-1 is a promising therapeutic target for autoimmune diseases
001379 Motomu Hashimoto [Japon] ; Moritoshi Furu [Japon] ; Wararu Yamamoto [Japon] ; Takanori Fujimura [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Akira Ohnishi [Japon] ; Kengo Akashi [Japon] ; Shuzo Yoshida [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Toru Hirano [Japon] ; Kosuke Ebina [Japon] ; Ryuji Uozumi [Japon] ; Hiromu Ito [Japon] ; Masao Tanaka [Japon] ; Koichiro Ohmura [Japon] ; Takao Fujii [Japon] ; Tsuneyo Mimori [Japon]Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
001414 Kosuke Ebina [Japon] ; Motomu Hashimoto [Japon] ; Wataru Yamamoto [Japon] ; Akira Ohnishi [Japon] ; Daijiro Kabata [Japon] ; Toru Hirano [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Shuzo Yoshida [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Kengo Akashi [Japon] ; Takanori Fujimura [Japon] ; Makoto Hirao [Japon] ; Keiichi Yamamoto [Japon] ; Ayumi Shintani [Japon] ; Atsushi Kumanogoh [Japon] ; Hideki Yoshikawa [Japon]Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
002026 Yoshihito Shima [Japon] ; Naoki Hosen ; Toru Hirano ; Junsuke Arimitsu ; Sumiyuki Nishida ; Keisuke Hagihara ; Masashi Narazaki ; Atsushi Ogata ; Toshio Tanaka ; Tadamitsu Kishimoto ; Atsushi KumanogohExpansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.
003460 Atsushi Ogata [Japon] ; Toru Hirano ; Yoshihiro Hishitani ; Toshio TanakaSafety and efficacy of tocilizumab for the treatment of rheumatoid arthritis.
003548 Toru Hirano [Japon] ; Nobuyuki Ohguro ; Satoshi Hohki ; Keisuke Hagihara ; Yoshihito Shima ; Masashi Narazaki ; Atsushi Ogata ; Kazuyuki Yoshizaki ; Atsushi Kumanogoh ; Tadamitsu Kishimoto ; Toshio TanakaA case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
003888 Sumiyuki Nishida [Japon] ; Tomio Kawasaki ; Hirokazu Kashiwagi ; Atsuyoshi Morishima ; Yoshihiro Hishitani ; Mari Kawai ; Toru Hirano ; Taeko Ishii ; Keisuke Hagihara ; Yoshihito Shima ; Masashi Narazaki ; Atsushi Ogata ; Yoshihiro Oka ; Tadamitsu Kishimoto ; Toshio TanakaSuccessful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab.
003A05 Atsushi Ogata [Japon] ; Atsuyoshi Morishima [Japon] ; Toru Hirano [Japon] ; Yoshihiro Hishitani [Japon] ; Keisuke Hagihara [Japon] ; Yoshihito Shima [Japon] ; Masashi Narazaki [Japon] ; Toshio Tanaka [Japon]Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab
003C43 Atsushi Ogata [Japon] ; Masahide Mori ; Shoji Hashimoto ; Yukihiro Yano ; Takeya Fujikawa ; Mari Kawai ; Yusuke Kuwahara ; Toru Hirano ; Junsuke Arimitsu ; Keisuke Hagihara ; Yoshihito Shima ; Masashi Narazaki ; Souichirou Yokota ; Tadamitsu Kishimoto ; Ichiro Kawase ; Toshio TanakaMinimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens.
003C90 Yoshihito Shima [Japon] ; Yusuke Kuwahara [Japon] ; Hiroyuki Murota [Japon] ; Shun Kitaba [Japon] ; Mari Kawai [Japon] ; Toru Hirano [Japon] ; Junsuke Arimitsu [Japon] ; Masashi Narazaki [Japon] ; Keisuke Hagihara [Japon] ; Atsushi Ogata [Japon] ; Ichiro Katayama [Japon] ; Ichiro Kawase [Japon] ; Tadamitsu Kishimoto [Japon] ; Toshio Tanaka [Japon]The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
003F01 Toshio Tanaka [Japon] ; Yusuke Kuwahara ; Yoshihito Shima ; Toru Hirano ; Mari Kawai ; Masako Ogawa ; Junsuke Arimitsu ; Keisuke Hagihara ; Masashi Narazaki ; Atsushi Ogata ; Ichiro Kawase ; Tadamitsu KishimotoSuccessful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
004045 Toshio Tanaka [Japon] ; Yusuke Kuwahara [Japon] ; Yoshihito Shima [Japon] ; Toru Hirano [Japon] ; Mari Kawai [Japon] ; Masako Ogawa [Japon] ; Junsuke Arimitsu [Japon] ; Keisuke Hagihara [Japon] ; Masashi Narazaki [Japon] ; Atsushi Ogata [Japon] ; Ichiro Kawase [Japon] ; Tadamitsu Kishimoto [Japon]Successful Treatment of Reactive Arthritis With a Humanized Anti-Interleukin-6 Receptor Antibody, Tocilizumab
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021